Human Genome Sciences completed its stock offering Monday, raising $357.6 million through the sell of 26.7 million shares to the public (which paid $14 per share) and underwriters. The Rockville, MD-based developer beat its own expectations after setting out to gain $310 million from a sale of 21.5 million shares. After hovering around 45 cents per share through the spring, the company's stock now trades above $14 per share, thanks to unexpectedly positive late-stage data from its experimental lupus drug Benlysta. Release